Dova is a clinical-stage pharmaceutical company

developing treatments for patients suffering from orphan diseases. The company’s lead investigational compound, avatrombopag, is in the process of completing two pivotal Phase 3 clinical trials researching its use as a potential treatment for thrombocytopenia in patients with chronic liver disease undergoing an elective procedure. The drug has not been approved by the FDA or other regulatory authorities for any use.

Contact us.

200 Garrett Street, Suite S
Charlottesville, VA 22902
P: 434.980.8100
F: 434.980.8199

Email us.